Novartis Just Pulled the Plug on Fabhalta's Biggest Ambition

This is why researchers got excited about complement inhibitors. The complement system is part of your immune defense (think of it as your body's alarm system for invaders), but in diseases like lupus nephritis, that alarm gets stuck in the "on" position and starts damaging healthy tissue. Blocking a piece of that system, specifically a protein called Factor B, is exactly what Fabhalta does.

The logic was sound. The biology made sense. But biology and clinical trials don't always agree.

Fabhalta's Report Card Everywhere Else

To be clear, this isn't a story about a failing drug. Fabhalta is thriving in its approved indications.

It first won approval for paroxysmal nocturnal hemoglobinuria (PNH), a rare blood disorder. Then came IgA nephropathy, a kidney disease where Fabhalta became the first complement inhibitor to significantly slow kidney function decline, cutting the rate of deterioration by 48% compared to placebo over two years. In July 2026, that earned a full FDA traditional approval. A third indication, C3 glomerulopathy (another rare kidney disease), followed shortly after, complete with Priority Review status from the FDA.

The sales trajectory tells the story of a drug on the rise. Fabhalta brought in $81 million in Q1 2025, then $149 million in Q3, then $155 million in Q4. By Q1 2026, it hit $169 million, more than doubling year over year. Novartis even secured approval in China for IgAN, expanding the drug's global footprint.

The lupus nephritis trial was supposed to be the next chapter: taking a proven complement blocker into a much larger autoimmune kidney market. Instead, it's a blank page.

The Competitive Landscape Just Got More Crowded

Fabhalta's retreat from lupus nephritis doesn't happen in a vacuum. The field is getting more competitive, and not just from other complement drugs.

In October 2025, obinutuzumab (a B-cell depleting antibody) won FDA approval for lupus nephritis in adults, becoming a major new standard-of-care option. That approval effectively raised the bar; any new entrant now has to prove it can beat or meaningfully add to an even stronger baseline therapy.

Other complement-targeted drugs are still in the race. Ravulizumab, a C5 inhibitor, has a Phase 2 lupus nephritis trial that is active but no longer recruiting. Pegcetacoplan, a C3 inhibitor, has shown early signals of reduced proteinuria (excess protein in urine, a key marker of kidney damage) in lupus nephritis patients. But neither has progressed to approval, and the evidence base remains thin compared to established B-cell approaches.

Beyond complement, the lupus nephritis pipeline is surprisingly crowded: CAR-T therapies, BAFF-receptor antibodies like ianalumab, JAK inhibitors like baricitinib, and more. It's a competitive traffic jam, and Novartis apparently decided Fabhalta didn't need to sit in it.

What This Means for Novartis's Complement Bet

The bull case for Fabhalta hasn't collapsed. Three approved indications, a clear sales ramp, and potential expansion into conditions like atypical hemolytic uremic syndrome and idiopathic membranous nephropathy still give the drug a long runway. Peak sales projections above $3 billion remain intact, with some analysts going even higher.

But the lupus nephritis pullback chips away at the "complement drugs can treat everything" narrative. It suggests that blocking the alternative complement pathway works beautifully in some kidney diseases and may not translate as cleanly to others, especially complex autoimmune conditions where complement is just one piece of a much larger puzzle.

Barron's reported that the stock held steady after the news, even as analysts questioned Novartis's growth story amid recent trial setbacks. Wall Street, for now, is treating this as a trim to long-term projections rather than a fundamental problem.

The Bigger Picture

For patients with lupus nephritis, the takeaway is frustratingly familiar: the unmet need persists. Current treatments leave too many people undertreated, and the complement pathway, which seemed like a promising new angle, just lost its most advanced champion in the space.

The remaining complement programs are earlier stage and smaller. They could still pan out, but the timeline just got longer. Meanwhile, drugs like obinutuzumab are filling part of the gap through different mechanisms.

Novartis made a calculated call. Walking away from a mid-stage trial isn't failure; it's resource allocation. The company clearly believes Fabhalta's future is brighter in rare kidney diseases than in the broader, messier world of lupus. Whether that bet is right depends on data we haven't seen yet, locked behind two words that tell us almost nothing: "strategic considerations."

BMS Just Paid $1.5 Billion for a Company With Zero Approved Drugs

Bristol Myers Squibb is dropping $1.5 billion in cash on Orbital Therapeutics, a preclinical-stage startup with zero approved drugs and zero revenue. The bet says everything about Big Pharma's platform fever and the desperate race to fill patent cliffs.